吉非替尼治疗晚期非小细胞肺癌临床观察

Clinical experience of treatment of patients with advanced non-small cell lung cancer by gefitinib(Iressa)

目的总结表皮生长因子受体酪氨酸激酶抑制剂吉非替尼治疗晚期非小细胞肺癌的临床经验及体会。方法从2005年5月至2007年1月有30例晚期非小细胞肺癌患者进入研究,所有患者均为Ⅲ至Ⅳ期,吉非替尼剂量为250mg/次,口服,每天1次。结果30例患者均可评价,获得PR7例(23.3%),SD12例(40.0%),PD11例(36.7%),总的疾病控制率63.3%。未出现3至4级的毒性反应。结论吉非替尼是一种比较有效的新型分子靶向治疗药物,不良反应轻微,可用于晚期非小细胞肺癌的治疗。

Objective To sum up the experience of treating non - small cell lung cancer（NSCLC） patients who took epidermal growth factor receptor（EGFR） -tyrosine kinase inhibitor Gefitinib （Iressa）. Methods 30 patients were collected from May, 2005 to Janu. 2007. Gefitinib was given, as a single drug, at a dose of 250 mg per day orally. Results Among these 30 patients, partial response 7 （23.3 % ）, stable disease 12 （ 40.0% ）, progressive disease 11 （ 36.7 % ）, 3 - 4 grades of toxic reaction were not found. Conclusion Gefitinib takes better effect on the patients with NSCLC. It provides a safe and effective way for the treatment of advanced non - small cell lung cancer.